2001 - Karo Bio

Karo Bio entered into a collaboration agreement with the Wyeth-Ayerst division of American Home Products, now known as Wyeth Pharmaceuticals, focusing on the Liver X receptor (LXR) with the goal of developing an entirely new drug for the prevention and treatment of atherosclerosis.

Bristol-Myers Squibb filed an IND and initiated Phase I clinical studies for an obesity treatment candidate jointly discovered with Karo Bio in their ongoing collaboration.
U.S. Patent granted to Karo Bio for desirable effects of thyroid hormone and thyroid analogs upon the composition of treated skin.
U.S. Patent granted on estrogen receptor beta crystal structures.
In collaboration with Abbott Laboratories, Karo Bio solved the glucocorticoid receptor three-dimensional structure.
A new technology for lead compound characterization and selection was in-licensed from Duke University, Durham, North Carolina.